Phase one study of synthetic antithrombin agent (MD-805) single and multiple administration studies - Nagasawa, H; Fukutake, K; Hada, M; Takahashi, E; Matubara, Y; Samori, T; Ikematsu, S; Kitahara, T; Ukita, M; Fujimaki, M; Fukutake, K (Jpn J. Clin Pharmacol Therap, 1981)